🦊/Investors

LifeSci Venture Partners β€” Full Portfolio

14 tracked investments Β· listed companies and verified rows first

Erascaerasca.comin𝕏NASDAQ: ERASApr 2020

Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.

BiotechDeep TechDigital HealthMedical DevicesSan Diego, US

Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)Gary Yeung, CFA(Chief Business Officer)in

BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)

Co-investorsAndreessen HorowitzARCH Venture PartnersEvolution VC PartnersFrazier Life SciencesCity Hill VenturesColt Ventures+1 more

RedHill Biopharma Ltdredhillbio.comNASDAQ: RDHL

BiotechTel Aviv

Shmuel Cabilly(Director)June Almenoff(Executive Officer)Ofer Tsimchi(Director)Rick D Scruggs(Executive Officer, Director)Nicolas Weinstein(Director)Alla Felder(Director)

PartnerPaul YookΒ· solo GP

Co-investorsHEALTHCARE ROYALTY PARTNERS

Senti Biosciencessentibio.comin𝕏NASDAQ: SNTI

Senti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells.

BiotechDeep TechMedical DevicesSouth San Francisco, US

Tim Lu(Co-Founder and Chief Executive Officer)inPhilip Lee(Executive Officer)inKanya Rajangam(President, Head of Research & Development and Chief Medical Officer)inYvonne Li(Executive Officer)inJames Collins(Director)

BoardDonald Tang(Director)

Co-investorsEvolution VC PartnersFlucas VenturesLifeforce CapitalLux CapitalMenlo VenturesNew Enterprise Associates (NEA)+10 more

Veradermicsveradermics.cominNYSE: MANE

Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.

BiotechHealthtechWest Hartford, US

Reid Waldman(Chief Executive Officer and Board Member)inTim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)

Co-investorsLongitude CapitalConnecticut InnovationsOUP (Osage University Partners)SR One Capital Managementabrdn plcInvus

Orasis Pharmaceuticalsorasis-pharma.comin𝕏Sep 2020 Β· $30Mβœ“ verified

Orasis is a pharmaceutical company developing drugs for the eye, operating in the ophthalmology and eyecare space.

BiotechHealthtechMedical Devices

Co-investorsArboretum VenturesMaverick Ventures IsraelVisionary VenturesCatalio Capital ManagementJohnson & Johnson Innovation – JJDCSequoia Capital+1 more

Antios Therapeuticsantiostherapeutics.comin𝕏Nov 2021 Β· $75M

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAisling CapitalAltium CapitalAvego BioScience CapitalPontifax Venture CapitalAmzak HealthDelos Capital+8 more

Biolinqbiolinq.comin

Biolinq develops the Shine sensor, a needle-free glucose monitor that measures glucose along with physical activity and sleep in a single wearable device.

Digital HealthHardwareMedical Devices

Jared Tangney(Founder)inRich Yangin

Co-investorsAble PartnersAlpha Wave GlobalAphelion CapitalAverin CapitalBOLD LongevityFeatures Capital Holdings+3 more

Biolinqbiolinq.mein

Biolinq develops a non-invasive glucose sensor that uses light to display glucose levels in real time, while also tracking activity and sleep to provide personalized health insights via a mobile app.

BiotechDigital HealthHealthtechMedical DevicesSan Diego, US

Jared Tangney(Executive Officer, Director, Promoter)inRichard Yang(Executive Officer, Director)Edward Kliphuis(Director)

BoardDaniel Bradbury(Director)inLana Ghanem(Director)

Co-investorsAlpha Wave GlobalBeyond CapitalBioBritJDRF T1D FundAphelion CapitalHikma Ventures+1 more

Clade TherapeuticsinNov 2021 Β· $87M

BiotechCambridge, US

Chad A. Cowan(Executive Officer, Director)inLeandro Vetcher(Executive Officer)Daniel Vasella(Director)Jim Glasheen(Executive Officer, Director)Neil White(Director)

BoardMartin Murphy(Director)

Co-investorsBain Capital Life SciencesCasdin CapitalVenrock Healthcare Capital Partners

Engage Therapeuticsengagetherapeutics.comin𝕏

Company whose formation and launch the LifeSci team supported.

BiotechHealthtechSummit, US

Gregory Mayes(Executive Officer, Director, Promoter)Jouko Isojarvi(Executive Officer)Stephen D. Collins(Director)Warren Lammert(Director)inOrrin Devinsky(Director)

BoardGerry Brunk(Director)in

PartnerPaul YookΒ· solo GP

Co-investorsLumira Ventures

Iridiairidia.comin𝕏

Iridia develops Molecular Avatar Technology that embeds unalterable molecular identities and custom data (text, image, audio, or video) into physical products and materials such as paints, coatings, plastics, and liquids.

BiotechDeep TechNew Materials

PartnerPaul YookΒ· solo GP

Co-investorsConnecticut InnovationsDuke Capital PartnersLongley CapitalPrime Movers Lab

MOMA Therapeuticsmomatx.comin𝕏May 2022 Β· $150M

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in

Co-investorsNextech InvestThird Rock VenturesAlexandriaCasdin CapitalCreacion VenturesGoldman Sachs+3 more

Other

Tracked investments with no reachable website or further public details β€” typically companies that wound down, renamed, or were absorbed.

Dodo OmniDataThar Pharmaceuticals

Rows marked β€œSEC filing” are inferred from directors named on the company's SEC Form D β€” public regulatory data, not a portfolio list published by the firm.